ATE501730T1 - Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten - Google Patents

Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten

Info

Publication number
ATE501730T1
ATE501730T1 AT02760986T AT02760986T ATE501730T1 AT E501730 T1 ATE501730 T1 AT E501730T1 AT 02760986 T AT02760986 T AT 02760986T AT 02760986 T AT02760986 T AT 02760986T AT E501730 T1 ATE501730 T1 AT E501730T1
Authority
AT
Austria
Prior art keywords
antagonist
treating psoriasis
antibody
il17d29
polypeptide
Prior art date
Application number
AT02760986T
Other languages
English (en)
Inventor
Emma Moore
Kevin Foley
Karen Madden
Yue Yao
Scott Presnell
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE501730T1 publication Critical patent/ATE501730T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02760986T 2001-01-25 2002-01-24 Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten ATE501730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26421901P 2001-01-25 2001-01-25
PCT/US2002/002244 WO2002102411A2 (en) 2001-01-25 2002-01-24 Method for treating psoriasis by using an il-17d antagonist

Publications (1)

Publication Number Publication Date
ATE501730T1 true ATE501730T1 (de) 2011-04-15

Family

ID=23005084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760986T ATE501730T1 (de) 2001-01-25 2002-01-24 Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten

Country Status (8)

Country Link
US (2) US20070048318A1 (de)
EP (2) EP2366406A1 (de)
AT (1) ATE501730T1 (de)
AU (1) AU2002326285A1 (de)
CA (1) CA2435151A1 (de)
DE (1) DE60239450D1 (de)
ES (1) ES2360481T3 (de)
WO (1) WO2002102411A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
JP2007535930A (ja) * 2004-05-03 2007-12-13 シェーリング コーポレイション 皮膚の炎症を予測するためのil−17発現の使用;処置方法
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP2010508856A (ja) * 2006-11-08 2010-03-25 ザイモジェネティクス,インコーポレイティド トランスフォーミング増殖因子β−9の変異体及びその使用方法
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US11866700B2 (en) 2016-05-06 2024-01-09 Exicure Operating Company Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610526B2 (en) * 1998-03-13 2003-08-26 Inctye Corporation Human E1-like protein
EP1082433A4 (de) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukine 21 und 22
US20070256145A1 (en) * 1998-09-17 2007-11-01 Presnell Scott R Mammalian transforming growth factor beta-9
CA2343569C (en) * 1998-09-17 2010-09-14 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9
US20040132136A1 (en) * 1998-09-17 2004-07-08 Zymogenetics, Inc. Mammalian Transforming growth factor beta-9
AU3207000A (en) * 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
AR028256A1 (es) * 2000-03-16 2003-04-30 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US20040115191A1 (en) * 2002-01-24 2004-06-17 Moore Emma E Method for treating psoriasis
EP1871399B1 (de) * 2005-04-18 2011-01-26 SC Dicophar Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
US9355528B2 (en) 2013-09-17 2016-05-31 Igt Gaming system and method for providing a cascading symbol game with shifting symbols between multiple symbol display position matrices
TWI616792B (zh) 2017-05-03 2018-03-01 友達光電股份有限公司 觸控顯示裝置的製造方法

Also Published As

Publication number Publication date
US20070048318A1 (en) 2007-03-01
WO2002102411A3 (en) 2003-09-18
DE60239450D1 (de) 2011-04-28
CA2435151A1 (en) 2002-12-27
EP2366406A1 (de) 2011-09-21
US20070280936A1 (en) 2007-12-06
ES2360481T3 (es) 2011-06-06
EP1359938B1 (de) 2011-03-16
EP1359938A2 (de) 2003-11-12
WO2002102411A2 (en) 2002-12-27
AU2002326285A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
DE60043957D1 (de) Verfahren zur Behandlung von Entzündungen
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE368095T1 (de) Verfahren zur herstellung von mitteldistillaten
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
DE60232956D1 (de) Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
DE50301171D1 (de) Verfahren zur chargenweise Beschichtung von Sägedraht
ATE481101T1 (de) Verfahren zur behandlung von angstzuständen
DE502004004681D1 (de) Verfahren zur herstellung von salzen schwach koordinierender aniomen, derartige salze sowie deren verwendung
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
DE60239450D1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
DE602004026253D1 (de) Verfahren zur Herstellung von Stahlbrammen mit ultra-geringem Kohlenstoffgehalt
ATE537173T1 (de) Verfahren zur herstellung von cucurbiturilen
DE69921450D1 (de) Verfahren zur herstellung von behandelter kieselsäure
DE60131545D1 (de) Verfahren zur behandlung von reaktiver arthritis oder schleimbeutelentzündung
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
ATE532620T1 (de) Vorrichtung und verfahren zum temperieren von vorformlingen
DE60324901D1 (de) Verfahren zur oberflächenreinigung von verunreinigungen enthaltendem graphit mittels einer nh4f und h2so4 enthaltenden wässrigen lösung
ATE334174T1 (de) System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen
ATE405659T1 (de) Verfahren zur modulierung von cytokininabhängigen vorgängen in einer pflanze mittels b3-domäne- proteinen
ATE428721T1 (de) Verfahren zur herstellung von wachstumshormon und antagonisten davon mit geringeren konzentrationen an isoformen verunreinigungen davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1359938

Country of ref document: EP